Related Experiment Video

Updated: Jan 24, 2026

Patient-derived Heterogeneous Xenograft Model of Pancreatic Cancer Using Zebrafish Larvae as Hosts for Comparative Drug Assessment
09:56

Patient-derived Heterogeneous Xenograft Model of Pancreatic Cancer Using Zebrafish Larvae as Hosts for Comparative Drug Assessment

Published on: April 30, 2019

9.6K

GATA1 Promotes Gemcitabine Resistance in Pancreatic Cancer through Antiapoptotic Pathway

Zhenyu Chang1, Yanan Zhang2, Jie Liu2

  • 1Department of Hepatobiliary and Pancreatic Surgical Oncology, Medical School of Chinese People's Liberation Army, Beijing 100853, China.

Journal of Oncology
|May 17, 2019
PubMed

Insights

The transcription factor GATA binding protein 1 (GATA1) drives gemcitabine resistance in pancreatic cancer by increasing Bcl-XL expression and promoting anti-apoptosis. Targeting GATA1 offers a potential strategy to improve chemotherapy response.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Gemcitabine chemotherapy is standard for pancreatic cancer but faces significant chemoresistance, limiting patient outcomes.
  • Developing strategies to overcome gemcitabine resistance is crucial for improving pancreatic cancer treatment efficacy.

Purpose of the Study:

  • To investigate the role of transcription factor GATA binding protein 1 (GATA1) in mediating gemcitabine resistance in pancreatic cancer.
  • To explore GATA1 as a potential therapeutic target to enhance gemcitabine efficacy.

Main Methods:

  • Analysis of GATA1 expression in pancreatic ductal adenocarcinoma (PDAC) tissues.
  • Investigation of GATA1's role in intrinsic and acquired gemcitabine resistance in PDAC cells.
  • Mechanistic studies involving GATA1, Bcl-XL promoter binding, and apoptosis assays in vitro and in vivo.

Main Results:

  • GATA1 is highly expressed in PDAC and predicts poor prognosis and response to gemcitabine.
  • GATA1 upregulates Bcl-XL expression, leading to enhanced anti-apoptosis and gemcitabine resistance.
  • Bcl-XL expression correlates with GATA1 levels and predicts clinical outcomes in PDAC patients.

Conclusions:

  • GATA1 is a novel driver of gemcitabine resistance in pancreatic cancer via the antiapoptotic pathway.
  • GATA1 serves as a potential prognostic marker and therapeutic target for pancreatic cancer.
  • Combined targeting of GATA1 and Bcl-XL may represent a promising strategy to overcome chemoresistance.

More Related Videos

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies07:29

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

Published on: June 20, 2015

20.1K
Laparoscopic Radical Left Pancreatectomy for Pancreatic Cancer: Surgical Strategy and Technique Video10:04

Laparoscopic Radical Left Pancreatectomy for Pancreatic Cancer: Surgical Strategy and Technique Video

Published on: June 6, 2020

10.2K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
The Eukaryotic Promoter Region02:40

The Eukaryotic Promoter Region

The eukaryotic promoter region is a segment of DNA located upstream of a gene. It contains an RNA polymerase binding site, a transcription start site, and several cis-regulatory sequences.  The proximal promoter region is located in the vicinity of the gene and has cis-regulatory sequences and the core promoter. The core promoter is the binding site for RNA polymerase and is usually located between -35 and +35 nucleotides from the transcription start site. The distal promoter regions are...
18.7K
The Eukaryotic Promoter Region02:40

The Eukaryotic Promoter Region

3.8K
C4 Pathway and CAM01:27

C4 Pathway and CAM

Most plants use the C3 pathway for carbon fixation. However, some plants, such as sugar cane, corn, and cacti that grow in hot conditions, use alternative pathways to fix carbon and conserve energy loss due to photorespiration. Photorespiration is the process that occurs when the oxygen concentration is high. Under such conditions, the rubisco enzyme in the Calvin cycle binds O2 instead of CO2, which halts photosynthesis and consumes energy.
C4 Pathway
The C4 pathway is used by plants such as...
48.9K
Resistivity01:22

Resistivity

When a voltage is applied to a conductor, an electrical field is generated, and charges in the conductor feel the force due to the electrical field. The current density that results depends on the electrical field and the properties of the material. In some materials, including metals at a given temperature, the current density is approximately proportional to the electrical field. In these cases, the current density can be modeled as:
4.4K
Resistance01:19

Resistance

When a current moves through any conductor, the conductor causes some level of difficulty for the current to flow. The measure of that difficulty is known as the resistance of the material and is represented by R. Every material has its own resistance. In the case of conductors, heat is emitted whenever a current passes through them. Resistance depends on the resistivity of the material. Resistivity is a characteristic of the material used to fabricate electrical components, whereas the...
5.7K